Can red yeast rice & olive extract improve lipid profile and cardiovascular risk in metabolic syndrome? A double blind randomized controlled trial

Similar documents
WHOLE HEALTH: CHANGE THE CONVERSATION. Lipids Summary Clinical Tool

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

Safety and efficacy of Red Yeast Rice in dyslipidemia and cardiovascular risk reduction

Hermans et al. Trials (2017) 18:302 DOI /s

Key words: red yeast rice, Monascus purpureus, hyper - lipidemia, myopathy, dietary supplement, lovastatin

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

TECHNICAL REPORT OF EFSA

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Is Red Yeast Rice Tolerable in Treating Patients With Dyslipidemia Who Have Statin-Associated Myalgia?

AMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients with Very High Triglycerides Without Raising LDL- C: The MARINE Study

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

Olea europaea in hypertension & metabolic syndrome

Authorized Distributor and Co-Packer of ANKASCIN 568-R Ingredients & ANKASCIN 568 Plus+ Finished Products

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

MOLINA HEALTHCARE OF CALIFORNIA

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

Review of guidelines for management of dyslipidemia in diabetic patients

What Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives

Traditional Asian Soyfoods. Proven and Proposed Cardiovascular Benefits of Soyfoods. Reduction (%) in CHD Mortality in Eastern Finland ( )

Management of Post-transplant hyperlipidemia

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Joshua Shepherd PA-C, MMS, MT (ASCP)

New Guidelines in Dyslipidemia Management

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

B. Patient has not reached the percentage reduction goal with statin therapy

Seung-Hwan Lee, M.D., Ph.D.

Non-Drug Ways to Promote Health by Lowering Cholesterol

ANCHOR Study Results Overview

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Plant sterols/stanols for cholesterol lowering and prevention of cardiovascular disease

Total risk management of Cardiovascular diseases Nobuhiro Yamada

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

Dyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Proven and Proposed Cardiovascular Benefits of Soyfoods

Next generation pre, pro, and synbiotics

International Journal of Research and Development in Pharmacy and Life Sciences. Research Article

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Novel Therapeutic Strategies in Lipid Management: Lowering LDL C to Improve Patient Outcomes

Grade * High cholesterol. Since the 1970s, human studies have reported that red yeast lowers blood

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

The effect of restricted diet with olive oil versus fish oil combined with endurance exercise on Dyslipidemic females

Overview. The Mediterranean Diet: The Optimal Diet for Cardiovascular Health. No conflicts of interest or disclosures

Safety of Anacetrapib in Patients with or

The effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

Professor Clare Collins

Dr. Laurence Eyres ECG Ltd Associate Professor Marie Wong, Massey University Oils and Fats Specialist Group November 2013

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Chronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management. Fabio Mazza

Cholesterol Management Roy Gandolfi, MD

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

BIOCHEMISTRY BLOOD - SERUM Result Range Units

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

Screening of Monacolin K-high-yielding Monascus strain by combinative mutation treatment

Replacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins

JMSCR Vol 07 Issue 01 Page January 2019

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

The Framingham Coronary Heart Disease Risk Score

Dyslipedemia New Guidelines

New Guidelines in Dyslipidemia Management

Are Red Yeast Rice Supplements Safe and Effective Alternatives to Statin Therapy?

NATURAL INGREDIENTS TO SUPPORT HEART HEALTH a focus on Mediterranean botanical extracts

Introduction. Objective. Critical Questions Addressed

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

The Mediterranean Diet: The Optimal Diet for Cardiovascular Health

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction

Establishment of Efficacy of Intervention in those with Metabolic Syndrome. Dr Wendy Russell - ILSI Europe Expert Group

Imaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

No relevant financial relationships

Cardiovascular Complications of Diabetes

Whole Grains and Health: A Roundup of the Latest Research

Effect of olive oil & tomato lycopene combination on some CHD risk factors

What do the guidelines say about combination therapy?

Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker

Absolute cardiovascular disease risk management

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Pharmacy Drug Class Review

Sartore Giovanni, 1 Burlina Silvia, 1 Ragazzi Eugenio, 2 Ferraresso Stefania, 1 Valentini Romina, 1 and Lapolla Annunziata 1. 1.

Mediterranean Diet: Choose this heart-healthy diet option

Elevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with

Tracking a Killer Molecule

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

Learning Objectives. Patient Case

Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane

Natural Approaches to Cholesterol Deregulation

Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes

Food and plant bioactives for reducing cardiometabolic disease: How does the evidence stack up?

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

THE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES

PCSK9 Agents Drug Class Prior Authorization Protocol

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

Super Omega-3 EPA/DHA with Sesame Lignans & Olive Extract

Transcription:

Can red yeast rice & olive extract improve lipid profile and cardiovascular risk in metabolic syndrome? A double blind randomized controlled trial Prof. Dr. N. Hermans Department of Pharmaceutical Sciences, Research Group NatuRA Prof. Dr. V. Verhoeven Faculty of Medicine, Research Group ELIZA

Introduction 1

Outline Introduction Aim Material & methods - Study design - Biomarkers of metabolic stress - Biomarkers of oxidative stress Results Discussion Conclusion 2

Alberti et al., Circulation,120,2009 Introduction 3

Introduction 1. 2. 3. 4

Introduction STATINS HMGCoA-reductase inhibitors 5 Rang and Dale s Pharmacology, 6th ed., 2007

Aim Double blind placebo controlled randomized trial to study the efficacy of red yeast rice (RYR) olive fruit extract on 1. LDL and oxidative stress 2. serum lipid parameters, blood pressure, cardiovascular risk, side effects 6

Outline Introduction Aim Material & methods - Study design - Biomarkers of metabolic stress - Biomarkers of oxidative stress Results Discussion Conclusion 7

Material & Methods Study design Double blind Placebocontrolled N=50 Metabolic syndrome: NCEP ATP III + LDL > 160 mg/ dl RYR-olive Placebo 8 weeks N=26 N=24 Biomarkers of metabolic syndrome Biomarkers of oxidative stress 8

9

10

Material & Methods Study design Clinical parameters Waist circumference BMI Blood pressure Biochemical parameters Total Cholesterol LDL HDL apoa1 apob Triglycerides HbA1c 11

Material & Methods Study design Parameters of oxidative stress Oxidised LDL (OxLDL) Malondialdehyde (MDA) Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) 12

Material & Methods Biomarkers of oxidative stress MDA Oxidative degradation PUFA Plasma λ(ex) = 532 nm λ(em) = 553 nm 13

Material & Methods Biomarkers of oxidative stress OxLDL Plasma OxLDL ELISA (Mercodia) Lp-PLA 2 Plasma Lp-PLA 2 activity (PLAC-test) 14

Material & Methods RYR-olive fruit extract Red yeast rice (RYR) Asia - traditional medicine - used in food as food colorant, flavour enhancer Fermentation of rice by Monascus purpureus: secondary metabolites : monacolins 15

Material & Methods RYR-olive fruit extract Red yeast rice (RYR) 10 mg monacolin K Inhibition HMG-CoA reductase 2 forms BIOLOGICAL ACTIVITY lovastatin 16

Material & Methods RYR-olive fruit extract Olive fruit extract Main polyphenolic constituents: Antioxidative activity ê oxidation of LDL 10 mg hydroxytyrosol 17

Material & Methods RYR-olive fruit extract Olive fruit extract ê oxidation of LDL EFSA, EFSA Journal, 9, 2033 (2011) 18

Randomised Controlled Trials - 1 RCT, cross-over, multicenter, 3 weeks (200 men) 25 ml/day of olive oil: Material & Methods RYR-olive fruit extract Quantified on main polyphenols LOW PC: 2.7 mg/kg polyphenols no HO-tyrosol MEDIUM PC: 164 mg/kg polyphenols 28.5 mg/kg HO-tyrosol HIGH PC: 366 mg/kg polyphenols 63.5 mg/kg HO-tyrosol Biomarkers of lipid peroxidation Dose-effect relationship Weinbrenner et al., J Nutr, 134, 2314-2321 (2004); Covas et al., Ann Intern Med, 145. 333-341 (2006) 19

Dose-effect relationship Material & Methods RYR-olive fruit extract LOW PC: 2.7 mg/kg polyphenols no HO-tyrosol MEDIUM PC: 164 mg/kg polyphenols 28.5 mg/kg HO-tyrosol HIGH PC: 366 mg/kg polyphenols 63.5 mg/kg HO-tyrosol polyphenols, HO-tyrosol antioxidant activity Lipid peroxidation 20

Dose-effect relationship Material & Methods RYR-olive fruit extract VOO (Virgin olive oil): ROO (Refined olive oil): 629 mg/l polyphenols - 24,4 mg/l tyrosol; 63,5 mg/l hydroxytyrosol; 327,2 mg/l oleuropein derivatives 0 mg/l polyphenols 21 de la Torre-Carbot et al., J Nutr, 140, 501-508 (2010)

Material & Methods Analysis of test product Monacolin K Lovastatin HPLC-UV analysis of RYR 10.82 ± 0.84 mg monacolins/caps 22

Material & Methods Analysis of test product Hydroxytyrosol HPLC-UV analysis of hydroxytyrosol 9.32 ± 0.54 mg / caps hydroxytyrosol 23

Outline Introduction Aim Material & methods - Study design - Biomarkers of metabolic stress - Biomarkers of oxidative stress Results Discussion Conclusion 24

Results - biochemical Table 1: Comparison between alterations in biochemical parameters in intervention and control group 25

Results Clinical Table 2: Comparison between alterations in clinical parameters in intervention and control group 26 Verhoeven et al., BMC Complem. Altern. Med., 2015

Results Biomarkers of oxidative stress MDA Plasma MDA-levels at baseline & after 8 weeks of treatment in RYR-olive treated & placebo groups. 27 Hermans et al., J Funct Foods,submitted for public (2015)

Results Biomarkers of oxidative stress OxLDL 20% Plasma OxLDL-levels at baseline & after 8 weeks of treatment in RYRolive treated & placebo groups. ***: p<0,001 mean difference placebo-intervention groups. 28 Hermans et al., J Funct Foods,submitted for public (2015)

Results Biomarkers of oxidative stress Lp-PLA 2 7% Plasma Lp-PLA 2 -levels at baseline & after 8 weeks of treatment in RYR-olive treated & placebo groups. ***: p<0,001 mean difference placebo-intervention groups. 29 Hermans et al., J Funct Foods,submitted for public (2015)

Results Biomarkers of oxidative stress r=0,740 n=26 p<0,001 Correlation between the absolute difference in OxLDL & Lp-PLA2. 30

Results Cardiovascular risk Median CV risk in both groups: 2% Intervention group: 1-18% Control group: 1-46% After the intervention: lower risk in 8/26 in RYR-olive (mainly blood pressure) lower risk in 1/24 higher risk in 2/24 in control group 31

Outline Introduction Aim Material & methods - Study design - Biomarkers of metabolic stress - Biomarkers of oxidative stress Results Discussion Conclusion 32

Discussion RYR - olive (Monakolin K 10 mg; Hyroxytyrosol 10 mg) daily 8 weeks Total cholesterol ê 17 % LDL ê 24 % Triglyceride ê 9 % Blood pressure ê 7 % (10 mmhg) systolic 9 % (7 mmhg)diastolic OxLDL ê 20 % Lp-PLA2 ê 7 % 33

Discussion Study Type Aim N Dose Results Conclusion Heber et al., Am J Clin Nutr 1999 RCT-DB, 12 w Cholesterollowering effects of RYR compared to diet 83 2,4 g/dg RYR (~ 10mg MK) Reduction of LDL, TC, TG Significant reduction of TC, TG en LDL. Lin et al., Eur J Endocrinol 2005 RCT DB, 8 w Lipid lowering effects and safety of RYR 79 1,2 g/dg RYR (~11,5 mg MK) LDL: -28% TC: -22% TG: -16% HDL: NS Significant reduction of LDL, TC en TG. Well tolerated Tetsuo et al. 2008 RCT DB, 8 w Dose-effect study of RYR 60 100mg RYR (= 2 mg MK), 200mg RYR (= 4 mg MK) 100mg RYR: LDL: -17% TC: -9% 200mg RYR: LDL: -17% TC: -12% 100 mg RYR (2mg MK)/day: reduction of LDL en TC. 34

Discussion Study Type Aim N Dose Results Conclusion Gheith et al., Ind J Nephrol 2008 Open label, 12 m Efficacy and safety of RYR compared to fluvastatin in treatment of nephrotic dyslipidemia 72 0,6 g RYR 2x/day 20 mg statin/day TC fluva: -31% TC RYR: -54% Proteinuria Safe and effective in treatment of nephrotic dyslipidemia Liu et al., Am J Cardiol, 2008 RCT 4,5 j Effect of XZK in secondary prevention of AMI 4870 0,3 g XZK (= 2,5 3,2 mg MK) TC: -11% LDL: -18% (8w) XZK: reduced cholesterol level, 30% coronary events and mortality Mitchell et al., J Clin Lipidol 2012 RCT DB, 12 m Cholesterol lowering effects of nutritional drink with or without RYR 79 0,6 g/dg RGR (2,4 mg MK) drink with RYR: at 8w, TC: -14% at 8w, LDL: -8% RYR containing drink lowers LDL en TC. Well tolerated. 35

Discussion Statin intolerant (SAM) patients Study Type Aim N Dose Results Conclusion Venero et al., Am J Cardiol, 2010 > 4 w Dose-effect study and tolerance of RYR 25 1,2 g/day RYR TC: -15% LDL: -21% TGs: -6% HDL: -0,5% Mild reduction of TC and LDL. well-tolerated Becker et al., Ann Intern Med, 2009 RCT DB 24 w Effectivity and tolerance 62 3,6 g/dg RYR (3,6 mg MK) LDL: -21% vs placebo Therapeutic option for patients with SAM 36

Discussion- side effects 20/26 in intervention group: no side effects 21/24 participants in placebo group: no side effects Side effects Intervention group (26) Placebo group (24) Muscle ache 3 1 Muscle cramps 1 1 Muscle weakness 1 1 Arthralgia 1 2 Mild CK elevation (less than twice the cut off) was present in 4/26 vs 2/24. 37

Discussion - Challenges Treatment > 8 weeks > study population / statin intolerant patients Effect due to combination RYR-olive extract? synergistic,?? à Biomarkers of oxidative stress Quality: Batch control!! - monacolin K levels monacolin K/lovastatin ratio - hydroxytyrosol levels - citrinin 38

Discussion Citrinin? Mycotoxin formed during fermentation of rice may also be formed in stored grains & other plant food products (beans, fruits, spoiled dairy products, herbs & spices, ) Optimisation of RYR fermentation process: citrinin Nephrotoxic? Level of no concern for nephrotoxicity : < 0.2 µg/kg b.w. EC Regulation 212/2014 : max 2000 µg/kg RYR Screening of citrinin in RYR of study: <2.5 µg/kg RYR APB : screening RYR supplements on Belgian market : no significant contamination with citrinin 39 EFSA Journal 2012;10(3):2605; EC 212/2014

Conclusion RYR - olive extract (Monakolin K 10 mg; Hyroxytyrosol 10 mg) daily 8 weeks Total cholesterol ê 17 %, LDL ê 24 %, Triglyceride ê 12 % Blood pressure ê 10 mmhg systolic ê 7 mmhg diastolic Anti-oxidative : OxLDL ê 20 %, Lp-PLA2 ê 7 % << long term studies 4.5 years secondary prevention - coronary events/ mortality Liu et al.(2008) Well-tolerated statin intollerant patients? >> RCT in statin intollerant patients long-term Case reports Vercelli et al., J Am Geriatr Soc (2006); Mueller PS, Ann Int med, (2006); Prasad et al., Transplantation, (2002) 40

Acknowledgement Faculty of Medicine ELIZA Prof. Dr. V. Verhoeven Department of Pharmaceutical Sciences NatuRA Natural Products & Food Research and Analysis LEMP Prof. Dr. L. Van Gaal Prof. Dr. S. Apers Dr. A. Breynaert PhDs A. Van der Auwera 41

Thank you for your attention 42